Answers are grounded in this paper and cite their sources.
Oligonucleotides (oligos) have been under clinical development for approximately the past 30 years, beginning with antisense oligonucleotides (ASOs) and apatmers and followed about 15 years ago by siRNAs. During that lengthy period of time, numerous clinical trials have been performed and thousands of trial participants accrued onto studies. Of all the molecules evaluated as of January 2017, the regulatory authorities assessed that six provided clear clinical benefit in rigorously controlled trials. The story of these six is given in this review.
No takes yet. Share an insight, caveat, or question.
Stein et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: